- Home
- NWTN vs GOSS Comparison
NWTN vs GOSS Comparison
Compare NWTN & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NWTN
- GOSS
- Stock Information
- Founded
- NWTN 2016
- GOSS 2015
- Country
- NWTN United Arab Emirates
- GOSS United States
- Employees
- NWTN N/A
- GOSS N/A
- Industry
- NWTN Auto Manufacturing
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- NWTN Consumer Discretionary
- GOSS Health Care
- Exchange
- NWTN Nasdaq
- GOSS Nasdaq
- Market Cap
- NWTN 232.4M
- GOSS 237.9M
- IPO Year
- NWTN N/A
- GOSS 2019
- Fundamental
- Price
- NWTN $0.67
- GOSS $0.96
- Analyst Decision
- NWTN
- GOSS Strong Buy
- Analyst Count
- NWTN 0
- GOSS 5
- Target Price
- NWTN N/A
- GOSS $9.20
- AVG Volume (30 Days)
- NWTN 31.2K
- GOSS 1.0M
- Earning Date
- NWTN 01-01-0001
- GOSS 03-04-2025
- Dividend Yield
- NWTN N/A
- GOSS N/A
- EPS Growth
- NWTN N/A
- GOSS N/A
- EPS
- NWTN N/A
- GOSS N/A
- Revenue
- NWTN $583,000.00
- GOSS $105,322,000.00
- Revenue This Year
- NWTN N/A
- GOSS N/A
- Revenue Next Year
- NWTN N/A
- GOSS N/A
- P/E Ratio
- NWTN N/A
- GOSS N/A
- Revenue Growth
- NWTN N/A
- GOSS N/A
- 52 Week Low
- NWTN $0.53
- GOSS $0.50
- 52 Week High
- NWTN $8.74
- GOSS $1.60
- Technical
- Relative Strength Index (RSI)
- NWTN 35.30
- GOSS 54.23
- Support Level
- NWTN $0.68
- GOSS $0.83
- Resistance Level
- NWTN $1.01
- GOSS $1.18
- Average True Range (ATR)
- NWTN 0.12
- GOSS 0.10
- MACD
- NWTN -0.02
- GOSS -0.01
- Stochastic Oscillator
- NWTN 16.67
- GOSS 41.37
About NWTN NWTN Inc.
NWTN Inc is a pioneering smart electric vehicle company which aims to integrate avant-garde design, life-style personalization, IoT connectivity, and autonomous driving technology into a passenger-centric green premium mobility solution to the world.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.